Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SYN-010

Other · developed by Theriva Biologics

Phase 2 Most advanced trial (none active)
TOVX Developer
1 Registered trials

What is SYN-010?

SYN-010 is an investigational drug studied in Irritable Bowel Syndrome With Constipation (IBS-C).

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Theriva Biologics, Inc. (TOVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02493036 Phase 2 Irritable Bowel Syndrome With Constipation (IBS-C) Completed TOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Irritable Bowel Syndrome With Constipation (IBS-C)

More from Theriva Biologics

Follow TOVX, the company behind SYN-010

See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TOVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.